Institution
Natera
About: Natera is a based out in . It is known for research contribution in the topics: Aneuploidy & Population. The organization has 190 authors who have published 164 publications receiving 4589 citations. The organization is also known as: Natera (United States).
Topics: Aneuploidy, Population, Cell-free fetal DNA, Trisomy, Colorectal cancer
Papers
More filters
••
University College London1, Francis Crick Institute2, Natera3, University of Leicester4, Brigham and Women's Hospital5, Harvard University6, Institute of Cancer Research7, The Royal Marsden NHS Foundation Trust8, University of Manchester9, University of Birmingham10, University of Aberdeen11, Glenfield Hospital12, Middlesex University13, Royal Free Hospital14, Princess Alexandra Hospital15, Royal Surrey County Hospital16, Ashford University17, Cardiff University18, University Hospital of Wales19, Whittington Hospital20, Semmelweis University21, Technical University of Denmark22, Boston Children's Hospital23, Max Delbrück Center for Molecular Medicine24, Katholieke Universiteit Leuven25
TL;DR: It is shown that phylogenetic ct DNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
Abstract: The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence. The ability to track the evolutionary dynamics of early-stage lung cancer non-invasively in circulating tumour DNA (ctDNA) has not yet been demonstrated. Here we use a tumour-specific phylogenetic approach to profile the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) study participants, including one patient who was also recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release and analyse the tumour-volume detection limit. Through blinded profiling of postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are very likely to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
1,179 citations
••
TL;DR: This cohort study investigates the use of longitudinal data from ultradeep sequencing of cell-free DNA in Danish patients with colorectal cancer to find out if the data can be used to improve the prognosis of these patients.
Abstract: Importance Novel sensitive methods for detection and monitoring of residual disease can improve postoperative risk stratification with implications for patient selection for adjuvant chemotherapy (ACT), ACT duration, intensity of radiologic surveillance, and, ultimately, outcome for patients with colorectal cancer (CRC). Objective To investigate the association of circulating tumor DNA (ctDNA) with recurrence using longitudinal data from ultradeep sequencing of plasma cell-free DNA in patients with CRC before and after surgery, during and after ACT, and during surveillance. Design, Setting, and Participants In this prospective, multicenter cohort study, ctDNA was quantified in the preoperative and postoperative settings of stages I to III CRC by personalized multiplex, polymerase chain reaction–based, next-generation sequencing. The study enrolled 130 patients at the surgical departments of Aarhus University Hospital, Randers Hospital, and Herning Hospital in Denmark from May 1, 2014, to January 31, 2017. Plasma samples (n = 829) were collected before surgery, postoperatively at day 30, and every third month for up to 3 years. Main Outcomes and Measures Outcomes were ctDNA measurement, clinical recurrence, and recurrence-free survival. Results A total of 130 patients with stages I to III CRC (mean [SD] age, 67.9 [10.1] years; 74 [56.9%] male) were enrolled in the study; 5 patients discontinued participation, leaving 125 patients for analysis. Preoperatively, ctDNA was detectable in 108 of 122 patients (88.5%). After definitive treatment, longitudinal ctDNA analysis identified 14 of 16 relapses (87.5%). At postoperative day 30, ctDNA-positive patients were 7 times more likely to relapse than ctDNA-negative patients (hazard ratio [HR], 7.2; 95% CI, 2.7-19.0;P Conclusions and Relevance Circulating tumor DNA analysis can potentially change the postoperative management of CRC by enabling risk stratification, ACT monitoring, and early relapse detection.
454 citations
••
TL;DR: This study aims to develop a noninvasive prenatal test on the basis of the analysis of cell‐free DNA in maternal blood to detect fetal aneuploidy at chromosomes 13, 18, 21, X, and Y.
Abstract: Objective This study aims to develop a noninvasive prenatal test on the basis of the analysis of cell-free DNA in maternal blood to detect fetal aneuploidy at chromosomes 13, 18, 21, X, and Y. Methods A total of 166 samples from pregnant women, including 11 trisomy 21, three trisomy 18, two trisomy 13, two 45, X, and two 47,XXY samples, were analyzed using an informatics-based method. Cell-free DNA from maternal blood was isolated, amplified using a multiplex polymerase chain reaction (PCR) assay targeting 11000 single nucleotide polymorphisms on chromosomes 13, 18, 21, X, and Y in a single reaction, and sequenced. A Bayesian-based maximum likelihood statistical method was applied to determine the chromosomal count of the five chromosomes interrogated in each sample, along with a sample-specific calculated accuracy for each test result. Results The algorithm correctly reported the chromosome copy number at all five chromosomes in 145 samples that passed a DNA quality test, for a total of 725/725 correct calls. The average calculated accuracy for these samples was 99.92%. Twenty-one samples did not pass the DNA quality test. Conclusions This informatics-based method noninvasively detected fetuses with trisomy 13, 18, and 21, 45,X, and 47, XXY with high sample-specific calculated accuracies for each individual chromosome and across all five chromosomes. © 2012 John Wiley & Sons, Ltd.
324 citations
••
TL;DR: SNP-based noninvasive prenatal microdeletion screening is highly accurate and should be considered for the general pregnant population because clinically relevant microdeletes and duplications occur in >1% of pregnancies.
267 citations
••
TL;DR: The data from this large-scale report on clinical application of this single-nucleotide polymorphism-based noninvasive prenatal test in a mixed high- and low-risk population is consistent with performance in validation studies.
244 citations
Authors
Showing all 190 results
Name | H-index | Papers | Citations |
---|---|---|---|
Allison M. Ryan | 49 | 111 | 11289 |
Susan J. Gross | 38 | 107 | 4978 |
Bernhard Zimmermann | 37 | 115 | 5545 |
H. Van de Velde | 35 | 64 | 3211 |
Zachary Demko | 34 | 84 | 5451 |
Meenakshi Malhotra | 29 | 72 | 2647 |
Matthew Rabinowitz | 29 | 89 | 4212 |
Asim Siddiqui | 29 | 47 | 12328 |
Styrmir Sigurjonsson | 24 | 59 | 2944 |
Raheleh Salari | 22 | 49 | 2683 |
Johan Baner | 22 | 32 | 3259 |
Joshua E. Babiarz | 21 | 42 | 4344 |
Hsin-Ta Wu | 20 | 37 | 18867 |
Milena Banjevic | 19 | 39 | 2289 |
Robert J. Pelham | 18 | 34 | 5789 |